What's in Janssen-Cilag International NV's pipeline?

Janssen-Cilag International NV has 5 drugs in our index: 1 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Janssen-Cilag International NV's portfolio?

Top competitors by shared drug class: ANRS, Emerging Infectious Diseases, ASST Fatebenefratelli Sacco, Aarhus University Hospital, Ain Shams University, Alexza Pharmaceuticals, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/janssen-cilag-international-nv.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Janssen-Cilag International NV — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Janssen-Cilag International NV pipeline: 1 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
OROS hydromorphone HCl	OROS hydromorphone HCl	marketed	Opioid agonist	Mu-opioid receptor	Pain Management
darunavir (DRV, TMC114)	darunavir (DRV, TMC114)	phase 3	Protease inhibitor	HIV protease	Infectious diseases
double blind PR OROS methylphenidate	double blind PR OROS methylphenidate	phase 3	Central nervous system stimulant		Central Nervous System
open label PR OROS methylphenidate	open label PR OROS methylphenidate	phase 3	Central nervous system stimulant		Attention deficit hyperactivity disorder

Therapeutic area mix

Attention deficit hyperactivity disorder · 1
Central Nervous System · 1
Infectious diseases · 1
Pain Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

ANRS, Emerging Infectious Diseases · 1 shared drug class
ASST Fatebenefratelli Sacco · 1 shared drug class
Aarhus University Hospital · 1 shared drug class
Ain Shams University · 1 shared drug class
Alexza Pharmaceuticals, Inc. · 1 shared drug class
Alza Corporation, DE, USA · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
· 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Janssen-Cilag International NV:

Cite this brief

Drug Landscape (2026). Janssen-Cilag International NV — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/janssen-cilag-international-nv. Accessed 2026-05-16.